Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=4&sort=-principal_investigator
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-principal_investigator", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=-principal_investigator", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=5&sort=-principal_investigator", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=3&sort=-principal_investigator" }, "data": [ { "type": "Grant", "id": "15952", "attributes": { "award_id": "1K25AI196259-01", "title": "Modeling SARS-CoV-2 variant emergence from immunocompromised hosts", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32891, "first_name": "MARY KATHERINE BRADFORD", "last_name": "PLIMACK", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-04-02", "end_date": "2031-03-31", "award_amount": 161946, "principal_investigator": { "id": 44397, "first_name": "Katherine", "last_name": "Owens", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3410, "ror": "", "name": "FRED HUTCHINSON CANCER CENTER", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "This proposal describes a five-year research training program that will facilitate my ongoing transition from an applied mathematician to an independent, quantitative, multidisciplinary biomedical researcher. I will work closely with clinicians, mathematical modelers, bioinformaticians, evolutionary biologists, virologists and immunologists to develop a suite of mathematical models which will be validated against viral, immune, phylogenetic and epidemiolocal datasets. The goals of my proposal will be to: 1) understand the mechanisms facilitating generation of SARS-CoV-2 variants of concern (VOC) during prolonged infections in immunocompromised (IC) individuals, and 2) identify key bottle necks that limit the number of VOCs that predominate in the general population. SARS-CoV-2 is the appropriate virus for which to develop this modeling framework due to the availability of data, and ongoing incidence, but the approach will be widely applicable to other pathogens. The training program includes an outstanding group of mentors and collaborators. My scientific advisory committee consists of experts in modeling infectious diseases (Dr Josh Schiffer and Dr Dan Reeves), clinical care for IC individuals (Dr Josh Schiffer and Dr. Alpana Wahgmare), epidemiology (Dr Cheryl Cohen and Dr Dobromir Dimitrov), viral evolution (Dr JT McCrone and Dr Mahan Ghafari), and biostatistics and machine learning (Dr Ollivier Hyrien). This group is dedicated to ensuring the success of my project, and my career development as an independent researcher. The specific learning goals required for my successful transition to biomedical research will be accomplished through didactic coursework in virology, immunology, epidemiology and phylogenetics as well as conferences and professional training in the skills of a successful mentor and group leader. The research plan addresses a critically important clinical and public health issue. Prolonged SARS-CoV- 2 infections in IC individuals are the most likely source of most novel VOC, which have extended and strongly exacerbated the impact of the pandemic. Though these infections have had an outsized public health impact, clear guidance regarding clinical management and safety measures is lacking. Understanding the within-host evolution of SARS-CoV-2 is paramount to addressing these issues. Through accomplishing the aims of this proposal, Dr Owens will address critical gaps in our knowledge of SARS-CoV-2 evolution and create an in silico framework to study SARS-CoV-2 interventions at both individual and population level. Ultimately, this proposal will allow Dr Owens to influence the future of pandemic response research as well as build a self-sustaining program at the interface of mathematical modeling, immunology, viral dynamics, and viral evolution.", "keywords": [ "2019-nCoV", "Address", "Advisory Committees", "Aftercare", "Anatomy", "Award", "Biomedical Research", "Biometry", "COVID-19 impact", "COVID-19 incidence", "Calibration", "Cessation of life", "Clinical", "Clinical Management", "Clinical Trials", "Data", "Data Set", "Dedications", "Effectiveness of Interventions", "Ensure", "Epidemiology", "Evolution", "Frequencies", "General Population", "Generations", "Genetic", "Genetic Drift", "Genetic Recombination", "Goals", "Guidelines", "Health Policy", "Heterogeneity", "Immune", "Immune response", "Immunity", "Immunocompromised Host", "Immunologics", "Immunologist", "Immunology", "Incidence", "Individual", "Infection", "Intervention", "Kinetics", "Knowledge", "Learning", "Link", "Machine Learning", "Mathematics", "Measures", "Mentors", "Mentorship", "Modeling", "Mutate", "Mutation", "Neck", "Nucleotides", "Output", "Pattern", "Phylogenetic Analysis", "Population", "Program Sustainability", "Public Health", "Published Comment", "Recording of previous events", "Research", "Research Personnel", "Research Training", "Risk", "Risk Factors", "SARS-CoV-2 infection", "SARS-CoV-2 variant", "Safety", "Scientist", "Social Distance", "Source", "Testing", "Training", "Training Programs", "United States National Institutes of Health", "Vaccination", "Variant", "Viral", "Viral Genes", "Viral Load result", "Virus", "Virus Replication", "Work", "career", "career development", "chronic infection", "clinical care", "community transmission", "design", "epidemiologic data", "experience", "fitness", "future pandemic", "immunological status", "in silico", "ineffective therapies", "infectious disease model", "insight", "machine learning method", "mathematical model", "multidisciplinary", "novel", "pandemic impact", "pandemic preparedness", "pandemic response", "pathogen", "patient oriented", "pressure", "skills", "success", "symposium", "tool", "transmission process", "vaccine distribution", "variants of concern", "viral rebound", "virology" ], "approved": true } }, { "type": "Grant", "id": "15951", "attributes": { "award_id": "1K99HL183741-01", "title": "Modeling the Effect of Apolipoprotein LI Risk Variants on CVD Risk in African American E-cigarette Users Using Human Induced Pluripotent Stem-Cell-Derived Endothelial Cells", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 44395, "first_name": "KAREN MARY", "last_name": "NEILSON", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-04-01", "end_date": "2028-03-31", "award_amount": 127168, "principal_investigator": { "id": 44396, "first_name": "Jelena", "last_name": "Mustra Rakic", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2635, "ror": "", "name": "UNIVERSITY OF CALIFORNIA, SAN FRANCISCO", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "African American individuals face a disproportionately higher risk of tobacco-related cardiovascular diseases (CVD) than other races, a disparity not fully explained by traditional and socioeconomic risk factors. Despite lacking approval from the U.S. Food and Drug Administration (FDA) for their safety, e-cigarettes (e-cigs) have become increasingly popular, particularly among youth, and are now among the most commonly used tobacco products alongside traditional cigarettes. Approximately half of African American individuals carry at least one of two genetic variants (G1 and G2) of the apolipoprotein L1 (APOL1) gene, which are exceedingly rare in other populations. APOL1 is widely expressed, particularly in the vasculature. We have shown that carriers of APOL1 G1 and G2 variants have increased susceptibility to tobacco-related CVD, including stroke and coronary heart disease. Dysfunction of vascular endothelial cells (ECs) is a critical precursor to CVD. EC dysfunction also plays a key role in APOL1-associated pathology, including exacerbated renal issues and increased susceptibility to sepsis and severe COVID-19. Recent research indicates that, similar to cigarettes, both e-cigs and menthol—a flavor popular in the African American community—independently impair endothelial function. While studies, including those using induced pluripotent stem cell (iPSC)-derived ECs, demonstrate these effects, the specific impact of APOL1 risk variants on vascular health in African American tobacco product users remains unknown. The goal of the proposed research is to determine the effects of e-cigs, with and without menthol, on endothelial health, compare them to the effects of cigarettes, and identify potential molecular markers and pathways associated with CVD in African American users, with a focus on the APOL1 genotype. As such, this application aims to expand my background and expertise in modeling the CVD risk from tobacco products and to provide specific training in tobacco product-related in vitro assays, iPSC methodology, gene editing, and computational techniques. Building on my prior work in human studies, this research extends to the cellular level to address significant gaps in knowledge regarding the adverse effects of the most popular tobacco products, with and without menthol, among the African American population—a demographic long targeted by the tobacco industry marketing. To achieve this goal, I will use a robust in vitro platform of human iPSC-ECs to address the following aims: Aim K1) to determine the effect of e-cigs and cigarettes on markers of EC dysfunction in G1/G1 iPSC-ECs, Aim R1) to determine the effect of e-cigs and cigarettes on endothelial function in G2/G2 iPSC-ECs, and Aim R2) to determine the effect of e-cigs and cigarettes on inflammatory markers and lipid mediators of inflammation in G1/G1 and G2/G2 iPSC-ECs. This project will deepen our understanding of the adverse effects of widely used tobacco products on vascular health in the CVD-burdened African American population. It also aims to identify molecular markers of cardiovascular injury in this high-risk group, providing insights into the mechanisms of tobacco-related cardiovascular damage and supporting the development of targeted interventions.", "keywords": [ "Address", "Adverse effects", "African American", "African American population", "Aftercare", "Apolipoproteins", "Blood Vessels", "CCL2 gene", "CRISPR/Cas technology", "CXCL10 gene", "CXCR3 gene", "Cardiovascular Diseases", "Cardiovascular Models", "Cardiovascular system", "Cell Culture Techniques", "Cell Line", "Cell Physiology", "Cigarette", "Communities", "Computational Technique", "Coronary heart disease", "Development", "Disease", "Disease Management", "Disparity", "Electronic cigarette", "Endothelial Cells", "Endothelium", "Exhibits", "Exposure to", "Face", "Functional disorder", "Genes", "Genetic Markers", "Genotype", "Goals", "Health", "Human", "Impairment", "In Vitro", "Inflammation Mediators", "Inflammatory", "Interferon Type II", "Interleukin-1 beta", "Interleukin-6", "Intervention", "Ischemic Stroke", "Kidney", "Kidney Diseases", "Knowledge", "Link", "Marketing", "Menthol", "Mentors", "Modeling", "Molecular", "Molecular Target", "Pathology", "Pathway interactions", "Pattern", "Phase", "Phenotype", "Play", "Polyunsaturated Fatty Acids", "Population", "Predisposition", "Race", "Recording of previous events", "Research", "Risk", "Risk Factors", "Role", "Safety", "Sepsis", "Signal Transduction", "Smoker", "Smoking", "Stroke", "Study models", "TNF gene", "Tobacco", "Tobacco Industry", "Tobacco use", "Training", "United States Food and Drug Administration", "Variant", "Vascular Endothelial Cell", "Work", "Youth", "burden of illness", "cardiovascular disorder risk", "cardiovascular health", "cardiovascular injury", "cardiovascular risk factor", "cell injury", "cigarette smoking", "cigarette user", "clinically relevant", "combustible cigarette", "electronic cigarette use", "electronic cigarette user", "endothelial dysfunction", "genetic variant", "genome editing", "health disparity", "high risk", "high risk population", "human induced pluripotent stem cells", "improved", "in vitro Assay", "in vivo", "induced pluripotent stem cell", "inflammatory marker", "insight", "interest", "lipid mediator", "marginalized community", "molecular marker", "racial population", "risk variant", "severe COVID-19", "socioeconomics", "stem cell based approach", "tobacco products", "transcriptomics", "trend", "vaping", "vascular endothelial dysfunction", "vascular injury" ], "approved": true } }, { "type": "Grant", "id": "15950", "attributes": { "award_id": "1K08AI196255-01", "title": "Neutralizing antibody pressure on the evolution of SARS-CoV-2 variants.\"", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32891, "first_name": "MARY KATHERINE BRADFORD", "last_name": "PLIMACK", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-04-02", "end_date": "2031-03-31", "award_amount": 194160, "principal_investigator": { "id": 44394, "first_name": "Ian Alexander", "last_name": "Mellis", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3409, "ror": "", "name": "COLUMBIA UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "/ ABSTRACT: Rationale: SARS-CoV-2 evolution has led to the emergence of viral variants that evade existing immunity in the human population, which continue to pose a threat to global public health. It has proven challenging to predict which mutations will arise in future dominant viral variants, and, as a result, it is difficult to design vaccines that provide adequate protection against viruses that will circulate in future waves of infections. Our preliminary data show that viral variant evolution is most closely correlated with evasion of serum neutralizing antibodies, and that serum neutralizing antibody responses are shaped by immune imprinting to the ancestral D614G strain. This mentored career project aims to leverage these observations to develop an in vitro model for predicting where mutations will appear in the virus and to use that information to design updated vaccines. Candidate: As a Transfusion Medicine fellow with a PhD in Genomics and Computational Biology and two years of experience in virology and immunology research, I bring a unique complement of perspectives and skills to the analysis of viral and antigenic evolution and to vaccine design strategies. Further training in advanced BSL-2-compatible pseudovirus culture, mouse immunization, and computational structural biology will be central to the completion of the proposed project and to my development as an independent physician-scientist aiming to improve our understanding and mitigation of pathogen evolution. My primary mentor, Dr. David Ho, an international leader in virology, and my complementary multidisciplinary advisory team, will ensure my research and career development progress. Environment: The Ho laboratory at the Columbia University Irving Medical Center (CUIMC) is a world leader in the study of pandemic viruses, including SARS-CoV-2, with expertise in the characterization of viral variants and serum antibody analysis. The Ho lab has access to abundant resources and many collaborators, including leaders in pseudovirus construction, structural biology, and vaccine design. CUIMC also has a long track record of supporting junior physician-scientists on their paths to successful independent careers in academic medicine. Approach: We will test the central hypothesis that widespread early exposure to ancestral SARS-CoV-2 shapes the evolutionary trajectory of the virus and that such a trajectory can be modeled in vitro. In Aim 1 we will assess the impact of mouse serum neutralizing antibodies elicited by different immunization histories on mutational profiles in cultured BSL-2-rated pseudoviruses and correlate mutations with historical public health databases. In Aim 2, we will identify whether particular epitopes on the spike protein are particularly susceptible to the emergence of mutations under serum antibody selective pressure. In Aim 3, we will design and test novel COVID-19 vaccine candidates in mice based on observed mutations that arise in pseudoviruses. This project will enhance our understanding of SARS-CoV-2, provide a framework for in vitro modeling of antigenically variable pathogens, and contribute to vaccine design strategies.", "keywords": [ "2019-nCoV", "Advisory Committees", "Antibodies", "Antibody Response", "Antigenic Variation", "Antigens", "Biological Assay", "COVID-19", "COVID-19 booster", "COVID-19 vaccine", "Cessation of life", "Complement", "Computational Biology", "Data", "Databases", "Dengue", "Development", "Doctor of Philosophy", "Ensure", "Environment", "Epitopes", "Escape Mutant", "Evolution", "Exposure to", "Formulation", "Frequencies", "Future", "Genomics", "Growth", "Human", "Immune", "Immune response", "Immunity", "Immunization", "Immunize", "Immunology", "Impairment", "In Vitro", "Individual", "Infection", "Influenza", "International", "Junior Physician", "Laboratories", "Machine Learning", "Maps", "Measures", "Medical center", "Medicine", "Mentors", "Modeling", "Monoclonal Antibodies", "Mus", "Mutation", "Physicians", "Population", "Predisposition", "Proteins", "Public Health", "RNA vaccine", "Recording of previous events", "Research", "Resolution", "Resources", "SARS-CoV-2 spike protein", "SARS-CoV-2 variant", "Scientist", "Serum", "Shapes", "Structural Models", "System", "Testing", "Training", "Universities", "Update", "Vaccination", "Vaccine Design", "Vaccines", "Variant", "Vesicular stomatitis Indiana virus", "Viral", "Viral Genome", "Virus", "Work", "booster vaccine", "candidate identification", "career", "career development", "cohort", "design", "emerging virus", "experience", "exposure mixture", "genome sequencing", "imprint", "improved", "in vitro Model", "innovation", "multidisciplinary", "mutant", "mutation screening", "neutralizing antibody", "novel", "novel vaccines", "pandemic disease", "pandemic virus", "pathogen", "predictive modeling", "pressure", "public health intervention", "recurrent infection", "research and development", "skills", "structural biology", "therapy development", "transfusion medicine", "vaccine candidate", "vaccine development", "variants of concern", "virology" ], "approved": true } }, { "type": "Grant", "id": "15949", "attributes": { "award_id": "1UG3NS143075-01A1", "title": "miR-10b Gene Editing Therapy for Glioblastoma", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Neurological Disorders and Stroke (NINDS)" ], "program_reference_codes": [], "program_officials": [ { "id": 44392, "first_name": "KELLY WILL", "last_name": "SHEPPARD", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-04-01", "end_date": "2028-03-31", "award_amount": 790474, "principal_investigator": { "id": 44393, "first_name": "Anna M.", "last_name": "Krichevsky", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3408, "ror": "", "name": "BRIGHAM AND WOMEN'S HOSPITAL", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Malignant glioma, particularly glioblastoma (GBM), remains among the most lethal forms of cancer and represents a significant unmet need in current medicine. The median survival of GBM patients is approximately 15-20 months with highly aggressive standard care, and the five-year survival rate is about 5%. There are no effective therapies for the disease. Over the years, we accumulated evidence that GBM growth and invasiveness are closely regulated by microRNAs, small regulatory molecules that control gene expression and strongly contribute to gliomagenesis. We demonstrated that this class of molecules holds great promise as therapeutic targets for neuro-oncology. Our work led us to focus on miR-10b, a unique growth and invasion-promoting miRNA and common molecular target for GBM in adults (otherwise a highly heterogeneous class of brain malignancies). We identified miR-10b, essential for glioma growth, as a top and common therapeutic target for GBM. Inhibition of miR-10b using different strategies reduced tumor growth in all tested glioma cell and animal models. CRISPR/Cas9 gene-editing of miR-10b emerged as the most potent therapeutic strategy in mice, and it holds great promise for GBM patients. We developed potent and safe lipid nanoparticle (LNP) -based miR-10b editing formulation as a new class of precision medicine for GBM. Our objective is to advance this miR-10b editing drug (called miRTED) into a “first-in-human” clinical trial in subjects with GBM. The Specific Aims of this project are, in UG3 component (Discovery phase): 1) Finalize the efficacy of miRTED administration using diverse orthotopic GBM models, 2) Assess the toxicity and off-target effects of miRTED administration using human and rodent neuroglial cells, brain organoids, and mouse models to establish dosing guidelines, and during UH3 component (Development phase): 3) Partner with BPN team and selected contract research organization to manufacture preclinical and then GMP-grade clinical lots of the LNP, 4) Partner with BPN team and selected contract research organization to conduct IND-enabling mouse toxicology and biodistribution studies, and 5) Finalize the writing and filing of the IND application with the FDA. Due to glioma “addiction” to miR-10b, the new strategy is expected to be highly efficacious for most, if not all, GBM patients despite the heterogeneity of the disease. This approach is principally different from other gene therapies proposed for the GBM- that all target only a subpopulation of patients. It can be used in combination with, or ultimately replace, the current standard care. In addition, the LNP formulations developed in this project could provide a platform technology for precision medicine targeting other tumor vulnerabilities. Notably, the recent success of COVID mRNA vaccines and in vivo gene editing trials provide POCs for the efficacy, safety, and scalability of mRNA/LNPs and CRISPR/Cas9 components in humans.", "keywords": [ "Adult", "Allografting", "Angiogenesis Inhibitors", "Animal Model", "Animals", "Antisense Oligonucleotide Therapy", "Antisense Oligonucleotides", "Apoptosis", "BCL2L11 gene", "Biodistribution", "Brain", "Brain Neoplasms", "CDKN1A gene", "CDKN2A gene", "COVID-19", "CRISPR/Cas technology", "Cell Cycle", "Cell Differentiation process", "Cell model", "Cells", "Clinical Pathways", "Clinical Trials", "Cytoprotection", "Development", "Diagnosis", "Disease", "Dose", "Drug Formulations", "EGFRvIII Peptide", "Epidermal Growth Factor Receptor", "Excision", "Exhibits", "FDA approved", "FDA-approved drug", "Formulation", "Gene Expression", "Genes", "Gliadel", "Glioblastoma", "Glioma", "Gliomagenesis", "Growth", "Guidelines", "Human", "Immunocompetent", "Immunotherapy", "Invaded", "Investigational New Drug Application", "Lead", "Malignant Glioma", "Malignant Neoplasms", "Mediating", "Medicine", "Messenger RNA", "MicroRNAs", "Modeling", "Molecular Target", "Mus", "Mutation", "Neuroglia", "Neurons", "Newly Diagnosed", "Organoids", "Patients", "Peptide Vaccines", "Pharmaceutical Preparations", "Phase", "Play", "RNA Splicing", "RNA delivery", "RNA vaccine", "Recurrence", "Regimen", "Research Contracts", "Resistance", "Rodent", "Role", "Safety", "Schedule", "Signal Pathway", "Survival Rate", "System", "Testing", "Therapeutic", "Toxic effect", "Toxicology", "Transcriptional Activation", "Tumor Cell Nuclei", "Tumor Subtype", "U6 small nuclear RNA", "Work", "Writing", "Xenograft procedure", "addiction", "bevacizumab", "checkpoint inhibition", "chemoradiation", "chemotherapy", "clinical lot", "disease heterogeneity", "drug development", "effective therapy", "first-in-human", "gene therapy", "in vivo", "inhibitor", "lipid nanoparticle", "manufacture", "mouse model", "mutational status", "nerve stem cell", "neuro-oncology", "neurosurgery", "oligonucleotide therapeutics", "patient subsets", "pharmacokinetics and pharmacodynamics", "pre-clinical", "precision medicine", "pro-apoptotic protein", "standard care", "standard of care", "success", "symptomatic improvement", "targeted therapy trials", "targeted treatment", "technology platform", "temozolomide", "therapeutic genome editing", "therapeutic target", "tumor", "tumor growth", "uncontrolled cell growth", "uptake" ], "approved": true } }, { "type": "Grant", "id": "15938", "attributes": { "award_id": "3U01AI069911-20S3", "title": "East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional Consortium", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 44382, "first_name": "JOANAD'ARC C", "last_name": "ROE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-06-01", "end_date": "2026-05-31", "award_amount": 276896, "principal_investigator": { "id": 44383, "first_name": "AGGREY SEMWENDERO", "last_name": "SEMEERE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 44384, "first_name": "Kara Kay", "last_name": "Wools-Kaloustian", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 44385, "first_name": "CONSTANTIN THEODORE", "last_name": "YIANNOUTSOS", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 3402, "ror": "", "name": "INDIANA UNIVERSITY INDIANAPOLIS", "address": "", "city": "", "state": "IN", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary/Abstract: Our primary goal continues to be the provision of answers to questions that clinicians, governments, programs and international organizations consider central to the evolution and sustainability of their long term HIV care and treatment strategies for achieving the UNAIDS 2030 targets of 95-95-95 in the midst of the SARS-CoV-2 pandemic and changes in public health funding priorities. Our central hypothesis is that retention in the HIV care cascade and treatment outcomes are influenced by patient-level demographic, clinical, developmental, and behavioral factors, as well as, factors within the ambient health care and broader contextual environment. We will leverage our strengths, including robust working relationships with HIV treatment programs, a substantial harmonized regional database, plus broad experience in sampling-based methodologies and novel analytical approaches. Over the course of this research we will: SA-1: Describe movement through the HIV care cascade with a focus on identifying broader and health care environment contextual factors that influence optimal retention in care and viral suppression, in the face of global disruption due to the COVID-19 pandemic and changes in donor funding priorities. The Post COVID-19 Double-Sampling Cohort (Post COVID) will address the impact of broader contextual factors (COVID-19) while the Telehealth and Structural Adaptations project will address the impact of health care structure. SA-2: Examine the impact of developmental stage and behavioral factors on retention in the cascade and subsequent outcomes. The multiregional Adolescent and Young Adult Network of IeDEA (AYANI) and regional Measuring Adverse Pregnancy and Newborn Congenital Outcomes (MANGO) cohorts will assess the impact of developmental stage on the cascade, while the Syndemics cohort will address the impact of mental health on the cascade.SA- 3: Examine the immediate and long-term outcomes of people diagnosed with Tuberculosis (TB) with a focus on identifying and addressing factors associated with patient outcomes. The multiregional TB Sentinel Research Network (TB-SRN) will focus on understanding TB outcomes and long-term pulmonary complications including associated factors. SA-4: Explore the use of new technologies, including eHealth and machine (deep) learning to diagnose and manage HIV-associated cancers with a focus on Kaposi’s Sarcoma (KS) and Cervical Cancer. The KS Project will assess implementation of a Dermatology Telehealth Program and the Cervical Cancer Project will assess the implementation of cervical image capture with machine learning for cancer diagnoses and management. SA-5: Examine the epidemiology of NCD comorbidities and ART complications with a focus on the oldest and youngest-age groups affected by HIV. The multi-regional Sentinel Research Network (SRN) will address non-communicable diseases in people living with HIV (PLHIV) > 40 years and the regional MANGO Cohort will address complications of ART/HIV exposure on HIV-Exposed Infants.", "keywords": [ "2019-nCoV", "AIDS related cancer", "Achievement", "Acquired Immunodeficiency Syndrome", "Address", "Adolescent and Young Adult", "Affect", "Africa", "Behavioral", "COVID-19", "COVID-19 pandemic", "Caring", "Cervical", "Clinic", "Clinical", "Collaborations", "Communities", "Country", "Data", "Data Sources", "Databases", "Dermatology", "Development", "Diagnosis", "Disease", "Environment", "Epidemiology", "Evolution", "Funding", "Gender", "Genetic", "Geography", "Goals", "Government", "Grant", "HIV", "HIV/AIDS", "Health", "Health Care", "Home", "Image", "Infant", "International", "Joints", "Kaposi Sarcoma", "Kenya", "Knowledge", "Learning", "Liver diseases", "Longevity", "Machine Learning", "Malignant Neoplasms", "Malignant neoplasm of cervix uteri", "Measures", "Mental Depression", "Mental Health", "Methodology", "Methods", "Movement", "Newborn Infant", "Operations Research", "Outcome", "Patient-Focused Outcomes", "Patients", "Persons", "Policies", "Pregnancy", "Public Health", "Research", "Resource-limited setting", "Risk Factors", "Sampling", "Sentinel", "Statistical Methods", "Structure", "Tanzania", "Technology", "Telemedicine", "Treatment outcome", "Tuberculosis", "Tuberculosis diagnosis", "Uganda", "United Nations", "Viral", "age group", "antiretroviral therapy", "cancer diagnosis", "cardiovascular risk factor", "care outcomes", "co-infection", "cohort", "comorbidity", "contextual factors", "eHealth", "experience", "implementation evaluation", "implementation research", "insight", "new technology", "novel", "post-COVID-19", "programs", "pulmonary", "scale up", "substance use", "syndemic", "telehealth", "tool", "treatment guidelines", "treatment program", "treatment strategy" ], "approved": true } }, { "type": "Grant", "id": "15941", "attributes": { "award_id": "3U01AI069911-20S5", "title": "East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional Consortium", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 44382, "first_name": "JOANAD'ARC C", "last_name": "ROE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-06-01", "end_date": "2026-05-31", "award_amount": 195343, "principal_investigator": { "id": 44383, "first_name": "AGGREY SEMWENDERO", "last_name": "SEMEERE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 44384, "first_name": "Kara Kay", "last_name": "Wools-Kaloustian", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 44385, "first_name": "CONSTANTIN THEODORE", "last_name": "YIANNOUTSOS", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 3402, "ror": "", "name": "INDIANA UNIVERSITY INDIANAPOLIS", "address": "", "city": "", "state": "IN", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary/Abstract: Our primary goal continues to be the provision of answers to questions that clinicians, governments, programs and international organizations consider central to the evolution and sustainability of their long term HIV care and treatment strategies for achieving the UNAIDS 2030 targets of 95-95-95 in the midst of the SARS-CoV-2 pandemic and changes in public health funding priorities. Our central hypothesis is that retention in the HIV care cascade and treatment outcomes are influenced by patient-level demographic, clinical, developmental, and behavioral factors, as well as, factors within the ambient health care and broader contextual environment. We will leverage our strengths, including robust working relationships with HIV treatment programs, a substantial harmonized regional database, plus broad experience in sampling-based methodologies and novel analytical approaches. Over the course of this research we will: SA-1: Describe movement through the HIV care cascade with a focus on identifying broader and health care environment contextual factors that influence optimal retention in care and viral suppression, in the face of global disruption due to the COVID-19 pandemic and changes in donor funding priorities. The Post COVID-19 Double-Sampling Cohort (Post COVID) will address the impact of broader contextual factors (COVID-19) while the Telehealth and Structural Adaptations project will address the impact of health care structure. SA-2: Examine the impact of developmental stage and behavioral factors on retention in the cascade and subsequent outcomes. The multiregional Adolescent and Young Adult Network of IeDEA (AYANI) and regional Measuring Adverse Pregnancy and Newborn Congenital Outcomes (MANGO) cohorts will assess the impact of developmental stage on the cascade, while the Syndemics cohort will address the impact of mental health on the cascade.SA- 3: Examine the immediate and long-term outcomes of people diagnosed with Tuberculosis (TB) with a focus on identifying and addressing factors associated with patient outcomes. The multiregional TB Sentinel Research Network (TB-SRN) will focus on understanding TB outcomes and long-term pulmonary complications including associated factors. SA-4: Explore the use of new technologies, including eHealth and machine (deep) learning to diagnose and manage HIV-associated cancers with a focus on Kaposi’s Sarcoma (KS) and Cervical Cancer. The KS Project will assess implementation of a Dermatology Telehealth Program and the Cervical Cancer Project will assess the implementation of cervical image capture with machine learning for cancer diagnoses and management. SA-5: Examine the epidemiology of NCD comorbidities and ART complications with a focus on the oldest and youngest-age groups affected by HIV. The multi-regional Sentinel Research Network (SRN) will address non-communicable diseases in people living with HIV (PLHIV) > 40 years and the regional MANGO Cohort will address complications of ART/HIV exposure on HIV-Exposed Infants.", "keywords": [ "2019-nCoV", "AIDS related cancer", "Achievement", "Acquired Immunodeficiency Syndrome", "Address", "Adolescent and Young Adult", "Affect", "Africa", "Behavioral", "COVID-19", "COVID-19 pandemic", "Caring", "Cervical", "Clinic", "Clinical", "Collaborations", "Communities", "Country", "Data", "Data Sources", "Databases", "Dermatology", "Development", "Diagnosis", "Disease", "Environment", "Epidemiology", "Evolution", "Funding", "Gender", "Genetic", "Geography", "Goals", "Government", "Grant", "HIV", "HIV/AIDS", "Health", "Health Care", "Home", "Image", "Infant", "International", "Joints", "Kaposi Sarcoma", "Kenya", "Knowledge", "Learning", "Liver diseases", "Longevity", "Machine Learning", "Malignant Neoplasms", "Malignant neoplasm of cervix uteri", "Measures", "Mental Depression", "Mental Health", "Methodology", "Methods", "Movement", "Newborn Infant", "Operations Research", "Outcome", "Patient-Focused Outcomes", "Patients", "Persons", "Policies", "Pregnancy", "Public Health", "Research", "Resource-limited setting", "Risk Factors", "Sampling", "Sentinel", "Statistical Methods", "Structure", "Tanzania", "Technology", "Telemedicine", "Treatment outcome", "Tuberculosis", "Tuberculosis diagnosis", "Uganda", "United Nations", "Viral", "age group", "antiretroviral therapy", "cancer diagnosis", "cardiovascular risk factor", "care outcomes", "co-infection", "cohort", "comorbidity", "contextual factors", "eHealth", "experience", "implementation evaluation", "implementation research", "insight", "new technology", "novel", "post-COVID-19", "programs", "pulmonary", "scale up", "substance use", "syndemic", "telehealth", "tool", "treatment guidelines", "treatment program", "treatment strategy" ], "approved": true } }, { "type": "Grant", "id": "15937", "attributes": { "award_id": "3U01AI069911-20S6", "title": "East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional Consortium", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 44382, "first_name": "JOANAD'ARC C", "last_name": "ROE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-06-01", "end_date": "2026-05-31", "award_amount": 47470, "principal_investigator": { "id": 44383, "first_name": "AGGREY SEMWENDERO", "last_name": "SEMEERE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 44384, "first_name": "Kara Kay", "last_name": "Wools-Kaloustian", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 44385, "first_name": "CONSTANTIN THEODORE", "last_name": "YIANNOUTSOS", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 3402, "ror": "", "name": "INDIANA UNIVERSITY INDIANAPOLIS", "address": "", "city": "", "state": "IN", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary/Abstract: Our primary goal continues to be the provision of answers to questions that clinicians, governments, programs and international organizations consider central to the evolution and sustainability of their long term HIV care and treatment strategies for achieving the UNAIDS 2030 targets of 95-95-95 in the midst of the SARS-CoV-2 pandemic and changes in public health funding priorities. Our central hypothesis is that retention in the HIV care cascade and treatment outcomes are influenced by patient-level demographic, clinical, developmental, and behavioral factors, as well as, factors within the ambient health care and broader contextual environment. We will leverage our strengths, including robust working relationships with HIV treatment programs, a substantial harmonized regional database, plus broad experience in sampling-based methodologies and novel analytical approaches. Over the course of this research we will: SA-1: Describe movement through the HIV care cascade with a focus on identifying broader and health care environment contextual factors that influence optimal retention in care and viral suppression, in the face of global disruption due to the COVID-19 pandemic and changes in donor funding priorities. The Post COVID-19 Double-Sampling Cohort (Post COVID) will address the impact of broader contextual factors (COVID-19) while the Telehealth and Structural Adaptations project will address the impact of health care structure. SA-2: Examine the impact of developmental stage and behavioral factors on retention in the cascade and subsequent outcomes. The multiregional Adolescent and Young Adult Network of IeDEA (AYANI) and regional Measuring Adverse Pregnancy and Newborn Congenital Outcomes (MANGO) cohorts will assess the impact of developmental stage on the cascade, while the Syndemics cohort will address the impact of mental health on the cascade.SA- 3: Examine the immediate and long-term outcomes of people diagnosed with Tuberculosis (TB) with a focus on identifying and addressing factors associated with patient outcomes. The multiregional TB Sentinel Research Network (TB-SRN) will focus on understanding TB outcomes and long-term pulmonary complications including associated factors. SA-4: Explore the use of new technologies, including eHealth and machine (deep) learning to diagnose and manage HIV-associated cancers with a focus on Kaposi’s Sarcoma (KS) and Cervical Cancer. The KS Project will assess implementation of a Dermatology Telehealth Program and the Cervical Cancer Project will assess the implementation of cervical image capture with machine learning for cancer diagnoses and management. SA-5: Examine the epidemiology of NCD comorbidities and ART complications with a focus on the oldest and youngest-age groups affected by HIV. The multi-regional Sentinel Research Network (SRN) will address non-communicable diseases in people living with HIV (PLHIV) > 40 years and the regional MANGO Cohort will address complications of ART/HIV exposure on HIV-Exposed Infants.", "keywords": [ "2019-nCoV", "AIDS related cancer", "Achievement", "Acquired Immunodeficiency Syndrome", "Address", "Adolescent and Young Adult", "Affect", "Africa", "Behavioral", "COVID-19", "COVID-19 pandemic", "Caring", "Cervical", "Clinic", "Clinical", "Collaborations", "Communities", "Country", "Data", "Data Sources", "Databases", "Dermatology", "Development", "Diagnosis", "Disease", "Environment", "Epidemiology", "Evolution", "Funding", "Gender", "Genetic", "Geography", "Goals", "Government", "Grant", "HIV", "HIV/AIDS", "Health", "Health Care", "Home", "Image", "Infant", "International", "Joints", "Kaposi Sarcoma", "Kenya", "Knowledge", "Learning", "Liver diseases", "Longevity", "Machine Learning", "Malignant Neoplasms", "Malignant neoplasm of cervix uteri", "Measures", "Mental Depression", "Mental Health", "Methodology", "Methods", "Movement", "Newborn Infant", "Operations Research", "Outcome", "Patient-Focused Outcomes", "Patients", "Persons", "Policies", "Pregnancy", "Public Health", "Research", "Resource-limited setting", "Risk Factors", "Sampling", "Sentinel", "Statistical Methods", "Structure", "Tanzania", "Technology", "Telemedicine", "Treatment outcome", "Tuberculosis", "Tuberculosis diagnosis", "Uganda", "United Nations", "Viral", "age group", "antiretroviral therapy", "cancer diagnosis", "cardiovascular risk factor", "care outcomes", "co-infection", "cohort", "comorbidity", "contextual factors", "eHealth", "experience", "implementation evaluation", "implementation research", "insight", "new technology", "novel", "post-COVID-19", "programs", "pulmonary", "scale up", "substance use", "syndemic", "telehealth", "tool", "treatment guidelines", "treatment program", "treatment strategy" ], "approved": true } }, { "type": "Grant", "id": "15936", "attributes": { "award_id": "3U01AI069911-20S1", "title": "East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional Consortium", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 44382, "first_name": "JOANAD'ARC C", "last_name": "ROE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-06-01", "end_date": "2026-05-31", "award_amount": 317911, "principal_investigator": { "id": 44383, "first_name": "AGGREY SEMWENDERO", "last_name": "SEMEERE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 44384, "first_name": "Kara Kay", "last_name": "Wools-Kaloustian", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 44385, "first_name": "CONSTANTIN THEODORE", "last_name": "YIANNOUTSOS", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 3402, "ror": "", "name": "INDIANA UNIVERSITY INDIANAPOLIS", "address": "", "city": "", "state": "IN", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary/Abstract: Our primary goal continues to be the provision of answers to questions that clinicians, governments, programs and international organizations consider central to the evolution and sustainability of their long term HIV care and treatment strategies for achieving the UNAIDS 2030 targets of 95-95-95 in the midst of the SARS-CoV-2 pandemic and changes in public health funding priorities. Our central hypothesis is that retention in the HIV care cascade and treatment outcomes are influenced by patient-level demographic, clinical, developmental, and behavioral factors, as well as, factors within the ambient health care and broader contextual environment. We will leverage our strengths, including robust working relationships with HIV treatment programs, a substantial harmonized regional database, plus broad experience in sampling-based methodologies and novel analytical approaches. Over the course of this research we will: SA-1: Describe movement through the HIV care cascade with a focus on identifying broader and health care environment contextual factors that influence optimal retention in care and viral suppression, in the face of global disruption due to the COVID-19 pandemic and changes in donor funding priorities. The Post COVID-19 Double-Sampling Cohort (Post COVID) will address the impact of broader contextual factors (COVID-19) while the Telehealth and Structural Adaptations project will address the impact of health care structure. SA-2: Examine the impact of developmental stage and behavioral factors on retention in the cascade and subsequent outcomes. The multiregional Adolescent and Young Adult Network of IeDEA (AYANI) and regional Measuring Adverse Pregnancy and Newborn Congenital Outcomes (MANGO) cohorts will assess the impact of developmental stage on the cascade, while the Syndemics cohort will address the impact of mental health on the cascade.SA- 3: Examine the immediate and long-term outcomes of people diagnosed with Tuberculosis (TB) with a focus on identifying and addressing factors associated with patient outcomes. The multiregional TB Sentinel Research Network (TB-SRN) will focus on understanding TB outcomes and long-term pulmonary complications including associated factors. SA-4: Explore the use of new technologies, including eHealth and machine (deep) learning to diagnose and manage HIV-associated cancers with a focus on Kaposi’s Sarcoma (KS) and Cervical Cancer. The KS Project will assess implementation of a Dermatology Telehealth Program and the Cervical Cancer Project will assess the implementation of cervical image capture with machine learning for cancer diagnoses and management. SA-5: Examine the epidemiology of NCD comorbidities and ART complications with a focus on the oldest and youngest-age groups affected by HIV. The multi-regional Sentinel Research Network (SRN) will address non-communicable diseases in people living with HIV (PLHIV) > 40 years and the regional MANGO Cohort will address complications of ART/HIV exposure on HIV-Exposed Infants.", "keywords": [ "2019-nCoV", "AIDS related cancer", "Achievement", "Acquired Immunodeficiency Syndrome", "Address", "Adolescent and Young Adult", "Affect", "Africa", "Behavioral", "COVID-19", "COVID-19 pandemic", "Caring", "Cervical", "Clinic", "Clinical", "Collaborations", "Communities", "Country", "Data", "Data Sources", "Databases", "Dermatology", "Development", "Diagnosis", "Disease", "Environment", "Epidemiology", "Evolution", "Funding", "Gender", "Genetic", "Geography", "Goals", "Government", "Grant", "HIV", "HIV/AIDS", "Health", "Health Care", "Home", "Image", "Infant", "International", "Joints", "Kaposi Sarcoma", "Kenya", "Knowledge", "Learning", "Liver diseases", "Longevity", "Machine Learning", "Malignant Neoplasms", "Malignant neoplasm of cervix uteri", "Measures", "Mental Depression", "Mental Health", "Methodology", "Methods", "Movement", "Newborn Infant", "Operations Research", "Outcome", "Patient-Focused Outcomes", "Patients", "Persons", "Policies", "Pregnancy", "Public Health", "Research", "Resource-limited setting", "Risk Factors", "Sampling", "Sentinel", "Statistical Methods", "Structure", "Tanzania", "Technology", "Telemedicine", "Treatment outcome", "Tuberculosis", "Tuberculosis diagnosis", "Uganda", "United Nations", "Viral", "age group", "antiretroviral therapy", "cancer diagnosis", "cardiovascular risk factor", "care outcomes", "co-infection", "cohort", "comorbidity", "contextual factors", "eHealth", "experience", "implementation evaluation", "implementation research", "insight", "new technology", "novel", "post-COVID-19", "programs", "pulmonary", "scale up", "substance use", "syndemic", "telehealth", "tool", "treatment guidelines", "treatment program", "treatment strategy" ], "approved": true } }, { "type": "Grant", "id": "15940", "attributes": { "award_id": "3U01AI069911-20S4", "title": "East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional Consortium", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 44382, "first_name": "JOANAD'ARC C", "last_name": "ROE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-06-01", "end_date": "2026-05-31", "award_amount": 747173, "principal_investigator": { "id": 44383, "first_name": "AGGREY SEMWENDERO", "last_name": "SEMEERE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 44384, "first_name": "Kara Kay", "last_name": "Wools-Kaloustian", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 44385, "first_name": "CONSTANTIN THEODORE", "last_name": "YIANNOUTSOS", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 3402, "ror": "", "name": "INDIANA UNIVERSITY INDIANAPOLIS", "address": "", "city": "", "state": "IN", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary/Abstract: Our primary goal continues to be the provision of answers to questions that clinicians, governments, programs and international organizations consider central to the evolution and sustainability of their long term HIV care and treatment strategies for achieving the UNAIDS 2030 targets of 95-95-95 in the midst of the SARS-CoV-2 pandemic and changes in public health funding priorities. Our central hypothesis is that retention in the HIV care cascade and treatment outcomes are influenced by patient-level demographic, clinical, developmental, and behavioral factors, as well as, factors within the ambient health care and broader contextual environment. We will leverage our strengths, including robust working relationships with HIV treatment programs, a substantial harmonized regional database, plus broad experience in sampling-based methodologies and novel analytical approaches. Over the course of this research we will: SA-1: Describe movement through the HIV care cascade with a focus on identifying broader and health care environment contextual factors that influence optimal retention in care and viral suppression, in the face of global disruption due to the COVID-19 pandemic and changes in donor funding priorities. The Post COVID-19 Double-Sampling Cohort (Post COVID) will address the impact of broader contextual factors (COVID-19) while the Telehealth and Structural Adaptations project will address the impact of health care structure. SA-2: Examine the impact of developmental stage and behavioral factors on retention in the cascade and subsequent outcomes. The multiregional Adolescent and Young Adult Network of IeDEA (AYANI) and regional Measuring Adverse Pregnancy and Newborn Congenital Outcomes (MANGO) cohorts will assess the impact of developmental stage on the cascade, while the Syndemics cohort will address the impact of mental health on the cascade.SA- 3: Examine the immediate and long-term outcomes of people diagnosed with Tuberculosis (TB) with a focus on identifying and addressing factors associated with patient outcomes. The multiregional TB Sentinel Research Network (TB-SRN) will focus on understanding TB outcomes and long-term pulmonary complications including associated factors. SA-4: Explore the use of new technologies, including eHealth and machine (deep) learning to diagnose and manage HIV-associated cancers with a focus on Kaposi’s Sarcoma (KS) and Cervical Cancer. The KS Project will assess implementation of a Dermatology Telehealth Program and the Cervical Cancer Project will assess the implementation of cervical image capture with machine learning for cancer diagnoses and management. SA-5: Examine the epidemiology of NCD comorbidities and ART complications with a focus on the oldest and youngest-age groups affected by HIV. The multi-regional Sentinel Research Network (SRN) will address non-communicable diseases in people living with HIV (PLHIV) > 40 years and the regional MANGO Cohort will address complications of ART/HIV exposure on HIV-Exposed Infants.", "keywords": [ "2019-nCoV", "AIDS related cancer", "Achievement", "Acquired Immunodeficiency Syndrome", "Address", "Adolescent and Young Adult", "Affect", "Africa", "Behavioral", "COVID-19", "COVID-19 pandemic", "Caring", "Cervical", "Clinic", "Clinical", "Collaborations", "Communities", "Country", "Data", "Data Sources", "Databases", "Dermatology", "Development", "Diagnosis", "Disease", "Environment", "Epidemiology", "Evolution", "Funding", "Gender", "Genetic", "Geography", "Goals", "Government", "Grant", "HIV", "HIV/AIDS", "Health", "Health Care", "Home", "Image", "Infant", "International", "Joints", "Kaposi Sarcoma", "Kenya", "Knowledge", "Learning", "Liver diseases", "Longevity", "Machine Learning", "Malignant Neoplasms", "Malignant neoplasm of cervix uteri", "Measures", "Mental Depression", "Mental Health", "Methodology", "Methods", "Movement", "Newborn Infant", "Operations Research", "Outcome", "Patient-Focused Outcomes", "Patients", "Persons", "Policies", "Pregnancy", "Public Health", "Research", "Resource-limited setting", "Risk Factors", "Sampling", "Sentinel", "Statistical Methods", "Structure", "Tanzania", "Technology", "Telemedicine", "Treatment outcome", "Tuberculosis", "Tuberculosis diagnosis", "Uganda", "United Nations", "Viral", "age group", "antiretroviral therapy", "cancer diagnosis", "cardiovascular risk factor", "care outcomes", "co-infection", "cohort", "comorbidity", "contextual factors", "eHealth", "experience", "implementation evaluation", "implementation research", "insight", "new technology", "novel", "post-COVID-19", "programs", "pulmonary", "scale up", "substance use", "syndemic", "telehealth", "tool", "treatment guidelines", "treatment program", "treatment strategy" ], "approved": true } }, { "type": "Grant", "id": "15939", "attributes": { "award_id": "3U01AI069911-20S2", "title": "East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional Consortium", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 44382, "first_name": "JOANAD'ARC C", "last_name": "ROE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-06-01", "end_date": "2026-05-31", "award_amount": 121192, "principal_investigator": { "id": 44383, "first_name": "AGGREY SEMWENDERO", "last_name": "SEMEERE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 44384, "first_name": "Kara Kay", "last_name": "Wools-Kaloustian", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 44385, "first_name": "CONSTANTIN THEODORE", "last_name": "YIANNOUTSOS", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 3402, "ror": "", "name": "INDIANA UNIVERSITY INDIANAPOLIS", "address": "", "city": "", "state": "IN", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary/Abstract: Our primary goal continues to be the provision of answers to questions that clinicians, governments, programs and international organizations consider central to the evolution and sustainability of their long term HIV care and treatment strategies for achieving the UNAIDS 2030 targets of 95-95-95 in the midst of the SARS-CoV-2 pandemic and changes in public health funding priorities. Our central hypothesis is that retention in the HIV care cascade and treatment outcomes are influenced by patient-level demographic, clinical, developmental, and behavioral factors, as well as, factors within the ambient health care and broader contextual environment. We will leverage our strengths, including robust working relationships with HIV treatment programs, a substantial harmonized regional database, plus broad experience in sampling-based methodologies and novel analytical approaches. Over the course of this research we will: SA-1: Describe movement through the HIV care cascade with a focus on identifying broader and health care environment contextual factors that influence optimal retention in care and viral suppression, in the face of global disruption due to the COVID-19 pandemic and changes in donor funding priorities. The Post COVID-19 Double-Sampling Cohort (Post COVID) will address the impact of broader contextual factors (COVID-19) while the Telehealth and Structural Adaptations project will address the impact of health care structure. SA-2: Examine the impact of developmental stage and behavioral factors on retention in the cascade and subsequent outcomes. The multiregional Adolescent and Young Adult Network of IeDEA (AYANI) and regional Measuring Adverse Pregnancy and Newborn Congenital Outcomes (MANGO) cohorts will assess the impact of developmental stage on the cascade, while the Syndemics cohort will address the impact of mental health on the cascade.SA- 3: Examine the immediate and long-term outcomes of people diagnosed with Tuberculosis (TB) with a focus on identifying and addressing factors associated with patient outcomes. The multiregional TB Sentinel Research Network (TB-SRN) will focus on understanding TB outcomes and long-term pulmonary complications including associated factors. SA-4: Explore the use of new technologies, including eHealth and machine (deep) learning to diagnose and manage HIV-associated cancers with a focus on Kaposi’s Sarcoma (KS) and Cervical Cancer. The KS Project will assess implementation of a Dermatology Telehealth Program and the Cervical Cancer Project will assess the implementation of cervical image capture with machine learning for cancer diagnoses and management. SA-5: Examine the epidemiology of NCD comorbidities and ART complications with a focus on the oldest and youngest-age groups affected by HIV. The multi-regional Sentinel Research Network (SRN) will address non-communicable diseases in people living with HIV (PLHIV) > 40 years and the regional MANGO Cohort will address complications of ART/HIV exposure on HIV-Exposed Infants.", "keywords": [ "2019-nCoV", "AIDS related cancer", "Achievement", "Acquired Immunodeficiency Syndrome", "Address", "Adolescent and Young Adult", "Affect", "Africa", "Behavioral", "COVID-19", "COVID-19 pandemic", "Caring", "Cervical", "Clinic", "Clinical", "Collaborations", "Communities", "Country", "Data", "Data Sources", "Databases", "Dermatology", "Development", "Diagnosis", "Disease", "Environment", "Epidemiology", "Evolution", "Funding", "Gender", "Genetic", "Geography", "Goals", "Government", "Grant", "HIV", "HIV/AIDS", "Health", "Health Care", "Home", "Image", "Infant", "International", "Joints", "Kaposi Sarcoma", "Kenya", "Knowledge", "Learning", "Liver diseases", "Longevity", "Machine Learning", "Malignant Neoplasms", "Malignant neoplasm of cervix uteri", "Measures", "Mental Depression", "Mental Health", "Methodology", "Methods", "Movement", "Newborn Infant", "Operations Research", "Outcome", "Patient-Focused Outcomes", "Patients", "Persons", "Policies", "Pregnancy", "Public Health", "Research", "Resource-limited setting", "Risk Factors", "Sampling", "Sentinel", "Statistical Methods", "Structure", "Tanzania", "Technology", "Telemedicine", "Treatment outcome", "Tuberculosis", "Tuberculosis diagnosis", "Uganda", "United Nations", "Viral", "age group", "antiretroviral therapy", "cancer diagnosis", "cardiovascular risk factor", "care outcomes", "co-infection", "cohort", "comorbidity", "contextual factors", "eHealth", "experience", "implementation evaluation", "implementation research", "insight", "new technology", "novel", "post-COVID-19", "programs", "pulmonary", "scale up", "substance use", "syndemic", "telehealth", "tool", "treatment guidelines", "treatment program", "treatment strategy" ], "approved": true } } ], "meta": { "pagination": { "page": 4, "pages": 1424, "count": 14236 } } }